Home | Welcome to Contract Pharma   
Last Updated Sunday, September 21 2014
Print

Akorn Completes VersaPharm Acquisition



Published August 12, 2014
Akorn, Inc. has completed its acquisition of VPI Holdings Corp., the parent company of VersaPharm Inc., for $440 million, expanding its presence in the dermatology market. The transaction is expected to add $90 to $100 million in annual revenues. 
 
"We are excited to announce that we have completed the acquisition of VersaPharm," said Raj Rai, chief executive officer of Akorn. "This highly strategic acquisition further strengthens our niche portfolio and accelerates our long-term growth opportunities."


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On